News
November 20, 2012
Montreal, November 20, 2012 – The Canadian Generic Pharmaceutical Association (CGPA) today welcomed the announcement that the Government of Quebec will eliminate the Province’s "15-year rule". The measure was included in Quebec’s 2013 Budget.
October 24, 2012
Toronto, October 24, 2012 – Tendering for generic prescription medicines, as announced by Canada’s Premiers in July 2012, could result in drug shortages and delayed savings to Canada’s health-care system, according to a new study by two of Canada’s top academics on pharmaceutical policy.
October 12, 2012
October 12, 2012, Brussels and Toronto – The following is a joint statement by Greg Perry, Director General of the European Generic medicines Association (EGA) and Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA) on the negotiations for a Comprehensive Economic and Trade Agreement (CETA) between the European Union and Canada:
October 9, 2012
Toronto, October 9, 2012Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), today made the following statement regarding Canada’s admission to the Trans-Pacific Partnership (TPP) negotiations:
October 5, 2012
Toronto, October 5, 2012 – The Honourable Ed Fast, Minister of International Trade and Minister for the Asia-Pacific Gateway, announced the opening of three new Apotex scientific offices today during a trade mission to Saudi Arabia and Jordan.
September 17, 2012
Toronto, September 17, 2012The following is a statement by Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), regarding the latest round of negotiations for a Comprehensive Economic and Trade Agreement (CETA) between Canada and the European Union (EU), which begin in Ottawa today:
July 27, 2012
Toronto, July 27, 2012 – The following is a statement by Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), regarding the release of the report by the Council of the Federation Working Group on Health Care Innovation, From Innovation to Action.
June 27, 2012
Toronto, June 27, 2012 – New data on research and development spending in Canada by brand-name drug companies provides further proof that there is no link between longer market monopolies and increased investments. Demands for even longer monopolies in Canada must be rejected, Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA) said today.
June 19, 2012
Toronto, June 19, 2012Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), today made the following statement regarding the formal invitation received by Canada to join the Trans-Pacific Partnership (TPP) negotiations:
June 15, 2012
Toronto, June 15, 2012 – Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), made the following statement on today’s announcement regarding construction of a second bridge at the Windsor-Detroit border:
June 7, 2012
Toronto, June 7, 2012 – The release of 2011 Canadian prescription drug sales information by IMS Brogan shows that generic prescription medicines offer greater value than ever before for Canadians, Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), said today.
April 27, 2012
Toronto, April 27, 2012The following is a statement by Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), regarding the current negotiations for a Comprehensive Economic and Trade Agreement (CETA) between Canada and the European Union (EU):
April 21, 2012
Toronto, April 21, 2012The following is a statement by Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), regarding the Ontario government’s announced plans for further cuts to generic prescription drug prices:
March 16, 2012
OTTAWA and TORONTO, March 16, 2012 – The following is a joint statement by Russell Williams, President of Canada’s Research-Based Pharmaceutical Companies (Rx&D), and Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), regarding the Motion passed by the House of Commons on a National Drug Strategy:
March 12, 2012
OTTAWA and TORONTO, March 12, 2012 -- Canada's Research-Based Pharmaceutical Companies (Rx&D) and the Canadian Generic Pharmaceutical Association (CGPA) today announced their commitment and financial support in responding urgently to prescription drug shortages.
March 9, 2012
Toronto, March 9, 2012The following is a statement by Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), providing an update on shortages of prescription medicines in Canada:
March 8, 2012
Toronto, March 8, 2012The following is a statement by Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), regarding shortages of prescription medicines in Canada:
January 9, 2012
Toronto, January 9, 2012 – The use of generic prescription medicines has saved Canada’s health-care system nearly $26-billion since 2007, according to an analysis of Canadian retail prescription drug sales information released today by the Canadian Generic Pharmaceutical Association (CGPA).